Rules 4.7.3 and 4.10.3 ASX Listing Rules Appendix 4G (current at 17/7/2020) Page 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Arovella Therapeutics Limited ABN/ARBN Financial year ended: 35 090 987 250 30 June...
Appendix 4G
Filed with ASX · · 12 pages · English
On 6ix: 6ix.com/news/appendix-4g-46
Release
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Appendix 4E and Annual Report
- Notification regarding unquoted securities - ALA
- Investor Webinar Presentation
- Investor Webinar Registration
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Arovella Therapeutics
- Corporate Governance Statement
- Clinical manufacturing batch released, first site activated
- Notification of 2026 AGM Date
- 2026 ESG Report
- The path to first patient dosing
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics